Based on KLRG1, Jiang et al. developed an NK cell-targeting immunomodulating nano-adaptor (imNA) to promote NK cells engagement of tumor cells for better exertion of tumor cytotoxicity, including αFc-NP with anti-KLRG1 antibody and anti-PDL1 antibody 135. The gene discussed is CD274; the disease is neoplasm.